The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

• Published in: Nature genetics Vol. 11; no. 2; pp. 198 - 200
• Main Authors: Struewing, Jeffery P, Abeliovich, Dvorah, Peretz, Tamar, Avishai, Naaman, Kaback, Michael M, Collins, Francis S, Brody, Lawrence C
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 01-10-1995
• Subjects: Biological and medical sciences; BRCA1 Protein; Breast Neoplasms - epidemiology; Breast Neoplasms - genetics; Cloning, Molecular; Confidence Intervals; Cystic Fibrosis - genetics; Ethnic Groups - genetics; Exons; Female; Gene Frequency; Genetic Carrier Screening; Gynecology. Andrology. Obstetrics; Humans; Jews - genetics; Mammary gland diseases; Medical sciences; Neoplasm Proteins - genetics; Ovarian Neoplasms - epidemiology; Ovarian Neoplasms - genetics; Risk Factors; Sequence Deletion; Tay-Sachs Disease - genetics; Transcription Factors - genetics; Tumors; Human; Medical screening; Epidemiology; Population genetics; Mammary gland diseases; Gene frequency; Gene; Risk factor; Predisposition; Tumor; Mammary gland; Mutation; Jew
• ISSN: 1061-4036; 1546-1718
• DOI: 10.1038/ng1095-198

Since BRCA1, the first major gene responsible for inherited breast cancer, was cloned, more than 50 unique mutations have been detected in the germline of individuals with breast and ovarian cancer. In high-risk pedigrees, female carriers of BRCA1 mutations have an 80-90% lifetime risk of breast cancer, and a 40-50% risk of ovarian cancer. However, the mutation stats of individuals unselected for breast or ovarian cancer has not been determined, and it is not known whether mutations in such individuals confer the same risk of cancer as in individuals from the high-risk families studied so far. Following the finding of a 185delAG frameshift mutation in several Ashkenazi Jewish breast/ovarian families, we have determined the frequency of this mutation in 858 Ashkenazim seeking genetic testing for conditions unrelated to cancer, and in 815 reference individuals not selected for ethnic origin. We observed the 185delAG mutation in 0.9% of Ashkenazim (95% confidence limit, 0.4-1.8%) and in none of the reference samples. Our results suggest that one in a hundred women of Ashkenazi descent may be at especially high risk of developing breast and/or ovarian cancer.